International Association for the Study of Lung Cancer

At IASLC, Our Mission is

To Conquer Thoracic Cancers Worldwide

On Nearly Every Continent, Our Members Are Working Toward a World Without Lung and Thoracic Cancers

MembersXnumbers-info_graphic_0319636935317642360195

Journal of Thoracic Oncology

Lung and thoracic specialists count on the IASLC’s Journal of Thoracic Oncology to provide perspective on innovation in prevention, detention, diagnosis and cutting-edge treatments. As a leading medical journal focusing on lung and thoracic cancers, the journal is dedicated to presenting original research reviews and opinions from a wide range of disciplines within the medical community.

Go to the Journal

IASLC News

September 08, 2019

KEYNOTE 189: Tumor Mutational Burden Not Significantly Associated with ...

Tumor mutational burden was not significantly associated with efficacy of pembrolizumab plus chemotherapy or placebo plus chemotherapy as first-line therapy for metastatic nonsquamous non-small cell lung cancer, according to research reported today by Dr. M. Garassino from the Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. Dr. Garassino presented this new data today at the IASLC 2019 WCLC.

September 08, 2019

Phase 1 Study Shows Novel KRAS Inhibitor Well Tolerated by Patients ...

A clinical trial testing the toxicity of a KRAS inhibitor demonstrated early promising antitumor activity and few adverse side effects in patients with advanced non-small cell lung cancer harboring KRAS G12C mutation, according to research presented today at the IASLC 2019 World Conference on Lung Cancer, hosted by the International Association for the Study of Lung Cancer.

September 08, 2019

New KEYNOTE 021 Data Shows No Association with Tumor Mutational Burden

Researchers had previously reported data from the KEYNOTE 021 trial that showed antitumor activity for pembrolizumab plus platinum-based chemotherapy in untreated advanced nonsquamous non-small cell lung cancer patients.

View News Archive

Events

View Event Calendar

Join Now - Become a Member

Join the only network of specialists working together to conquer lung and thoracic cancers worldwide. As a member, you can collaborate with a global team of thoracic oncology experts and gain access to the latest, ground-breaking research in lung cancer prevention, detection and treatment.

Join Now